Skip to main content
Fig. 1 | BMC Psychiatry

Fig. 1

From: Using the drug repositioning approach to develop a novel therapy, tipepidine hibenzate sustained-release tablet (TS-141), for children and adolescents with attention-deficit/hyperactivity disorder

Fig. 1

Study Design of Phase II Clinical trial. The study was conducted in 2 periods, a 2-week observation period and an 8-week double-blind treatment period. Participants who meet all study criteria at baseline were randomized in a 1:1:1:1 ratio in a fixed daily dose of 30 mg (once a day), 60 mg (once a day), 120 mg (60 mg twice a day), or placebo. Each patient was randomized for each dose according to CYP2D6 phenotype as a stratification factor: UM and EM group, IM and PM group, or unknown group in CYP2D6 phenotype

Back to article page

BMC Psychiatry

ISSN: 1471-244X

Contact us